Carregant...

MULTI-DOMAIN TARGETING OF BCR-ABL BY DISRUPTION OF OLIGOMERIZATION AND TYROSINE KINASE INHIBITION: TOWARDS ERADICATION OF CML

The oncoprotein Bcr-Abl, the causative agent of chronic myeloid leukemia (CML), requires homo-oligomerization via a coiled-coil domain to function.(1–4) While tyrosine kinase inhibitors (TKIs) have shown great efficacy as treatment options for CML, their use may cause an acquisition of mutations in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Miller, Geoffrey D., Woessner, David W., Sirch, Monika J., Lim, Carol S.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3933093/
https://ncbi.nlm.nih.gov/pubmed/23915432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/mp400323c
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!